Skip to main content

Prenetics Global Ltd

corporate_fare Company Profile

Prenetics Global Ltd

PRE·NASDAQ·Life Sciences·CIK 0001876431

The company is a consumer health company that develops and sells science-backed products. It operates through two brands: IM8 and CircleDNA. IM8 is the company's flagship consumer health brand, co-founded with David Beckham. It generated $60.1 million in revenue in its first full fiscal year (FY2025) and achieved $120 million in annualized recurring revenue (ARR) as of December 2025. IM8 products are shipped to more than 30 countries. The brand's gross margin was approximately 63% in FY2025. In Q4 2025, IM8's monthly revenue reached $10.0 million, quarterly revenue was $27.4 million, and total customer orders exceeded 230,000. The average order value for IM8 in the last month of Q4 2025 was $133, and the new customer subscription rate was approximately 80%. CircleDNA is a complementary asset that generated $12.9 million in revenue in FY2025 with a gross margin of approximately 85%. The company's total revenue from continuing operations was $92.4 million in FY2025, an increase of 480% from $15.9 million in FY2024. Gross profit was $48.8 million in FY2025, representing a gross margin of 52.8%. The company reported a loss for the year of $(40.0) million in FY2025. In Q4 2025, the company's total revenue reached $36.6 million.

Prenetics Global Ltd (NASDAQ:PRE) is a publicly traded company in the Life Sciences sector. Wiseek monitors PRE SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Prenetics Reduces Potential Dilution by 43% Through Warrant Exchange Program
  • Prenetics Divests Europa Business for Up to $13M, Sharpens Focus on High-Growth IM8 Brand

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$92.39M
Net Income
-$39.98M
Diluted EPS
-$2.68
Op. Cash Flow
-$21.83M
Free Cash Flow
-$22.03M
Gross Profit
$48.79M
Operating Income
-$44.48M
Cash & Equivalents
$32.13M
Debt / Equity
0.00×
Net Margin
-43.3%
Source: 20-F · filed 2026-04-30 · accession 0001628280-26-028623

Insider Transactions

PRE files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$21.63
52-week range · as of 2026-06-10 $6.88 – $23.63
Market cap
$364M
Volume
348.6K (1.2× avg)
3-mo avg 279.8K
Live data · 2026-06-14 06:17 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PRE - Filings & News (Page 2)

PRE
Jan 05, 2026, 8:21 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $16.21
Real-time Price: $21.63 info
Change: +$5.42 (+33%) info
Market Cap: $363.999M info
PRE
Jan 06, 2026, 8:04 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $15.85
Real-time Price: $21.63 info
Change: +$5.78 (+36%) info
Market Cap: $363.999M info